Danone demands EFSA reveal “minority opinions” in Actimel health claim rejection response

By Shane Starling

- Last updated on GMT

Related tags Probiotic Gut flora

Danone wants to know if there were dissenting opinions among NDA health claim verdicts
Danone wants to know if there were dissenting opinions among NDA health claim verdicts
Global probiotics leader Danone has written a 14-page response to the European Food Safety Authority (EFSA) in which it accuses the Parma-based agency of ignoring positive trial data and demands to see “minority opinions” among health claim panel decisions.

The letter criticises EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) for failing to address points of concern Danone raised during three separate stop-the-clock procedures and says the NDA found trial faults including blinding procedures that had passed peer review procedures.

“We believe our comments can be an opportunity for risk assessors (EFSA) and risk managers (Commission and Member States) to clarify their respective positions,” ​wrote Danone Dairy vice president of research and development, Frederic René, and Pierre-Hubert Cuijpers, the division’s general counsel in food law, in their letter to Basil Mathioudakis, the EC’s unit head in Food Law, Nutrition and Labelling.

Key points raised in Danone’s letter include:

  • demand to see Assessment Methodology Unit (AMU) reports that are designed to guarantee transparency in the process
  • demand to see minority opinions that may have existed among some NDA panel members as mandated in article 38(1)(B) of EU regulation 178/2002
  • stop-the-clock not used by EFSA to air genuine concerns
  • inconsistent application of requirement to demonstrate “mechanisms of action”

Minority reporting

In regard to minority opinions Danone said it understood, “that the opinions are adopted in quorum and by a majority of the NDA Panel members. However, in the published opinion, it remains unclear whether there are or not members of the Panel who had different minority opinions.”

“Danone would like to know how the opinions of the members of the AMU are considered at this stage in light of [article 38(1)(B) of EU regulation 178/2002].”


Danone said it was “deplorable”​ that the NDA Panel had not raised issues it published in its final opinion at the stop-the-clock phase as Danone, “believed it could have brought the appropriate answers to the Panel”.

Mechanisms of action

The French dairy player said the requirement to demonstrate mechanisms of action, something which is only just emerging in probiotic science, had not been required in positive opinions for some vitamins and minerals.

More generally it said there was a necessity for, “regular open dialogue between applicants and EFSA” ​so applicants could better, “understand EFSA’s expectations and specific aspects of their health claim dossiers”.

The letter goes on to contest in detail various aspects of the article 14 NDA opinion published in December that can be found here.​ NutrIngredients coverage of it can be found here.

The maker of Actimel and Activia challenged why the Panel:

  • was not clear about whether the reduction of C. Difficile​ toxins was beneficial or not
  • took issue with transparent blinding measures the British Medical Journal ​did not and which were not raised in stop-the-clock exchanges
  • dismissed toxin assessment procedures as weakening the central trial in the dossier
  • deemed weak a chosen data imputation scenario for the same trial
  • dismissed supporting data on bioavailability and probiotic properties because it did not demonstrate effects on C. Difficile ​or effects in humans when it was intended and marked as ‘supporting data’ only

Danone had proposed the claim wording: “Fermented milk containing the probiotic Lactobacillus casei DN-114001 and yogurt symbiosis decreases presence of Clostridium difficile toxins in the gut (of susceptible ageing people). Presence of Clostridium difficile toxins is associated with the incidence of acute diarrhoea.”

Related news

Show more

Related products

show more

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Taking Immune Support to a New Level

Taking Immune Support to a New Level

Content provided by AB Biotek Human Nutrition & Health | 30-Oct-2023 | White Paper

Patent-pending ABB C1® redefines immune support by addressing innate, acquired, and Trained Immunity. In 'ABB C1®: Training Now for Future Immune...

Custom Biotic Solutions for Digestive Health

Custom Biotic Solutions for Digestive Health

Content provided by ADM: Innovation that Feeds the Future | 10-Oct-2023 | White Paper

A growing body of evidence shows gut health can affect digestive health, well-being, and many health areas in between.

Related suppliers

1 comment

Double Standard

Posted by Margaret Huffstickler,

There are huge numbers of pharmaceuticals on the market whose "mechanisms of action" are not known. Why do healthy foods have to provide this information for their health claims to be approved, when drugs, with frequently toxic side effects, do not?

Report abuse

Follow us


View more